Status: Recruiting
HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors
This is a single arm, open-label, dose escalation clinical study to evaluate the safety and efficacy of HRYZ-T102 TCR-T Cell in patients with AFP positive advanced hepatocellular carcinoma and other solid tumors refractory to prior systematic treatments.
Participants needed: 12
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shanghai Ruiliyuan Biotechnology Co., Ltd.Updated: Dec 2, 2025Locations: 1
Eligibility criteria
The patient must be willing to sign the informed consent form. [+9]
Toxicity of previous treatment has not been mitigated or ≤ Grade 1 at screening. [+14]